Karyopharm Therapeutics discovers and develops drugs for cancer treatment. The company focuses on Selective Inhibitor of Nuclear Export (SINE) compounds that target exportin 1 (XPO1). Its lead compound, XPOVIO, treats multiple myeloma and diffuse large B-cell lymphoma. Selinexor is being developed for hematological and solid tumor malignancies. The company has license agreements with Menarini Group, Antengene Therapeutics, and FORUS Therapeutics. Karyopharm also collaborates with Bristol Myers Squibb to evaluate mezigdomide in combination with Selinexor. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |